Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|3|352-355

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.3, 2015-05, pp. : 352-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 4, 2018-02 ,pp. : 534-544

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 188-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-05 ,pp. : 273-279

Karger

Access to resources Recommend Favorite

Bortezomib in Plasmablastic Lymphoma: A Case Report and Review of the Literature

By  

Oncology Research and Treatment, Vol. 36, Iss. 5, 2013-04 ,pp. : 287-291

Karger

Access to resources Recommend Favorite

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 229-230

Karger

Access to resources Recommend Favorite